Insulin Resistance - Pipeline Insight, 2024

This Insulin Resistance - Pipeline Insight, 2024,” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Insulin Resistance pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Insulin Resistance Understanding

Insulin Resistance: Overview

Insulin resistance is identified as an impaired biologic response to insulin stimulation of target tissues, primarily the liver, muscle, and adipose tissue. Insulin resistance impairs glucose disposal, resulting in a compensatory increase in beta-cell insulin production and hyperinsulinemia. The metabolic consequences of insulin resistance can result in hyperglycemia, hypertension, dyslipidemia, visceral adiposity, hyperuricemia, elevated inflammatory markers, endothelial dysfunction, and a prothrombic state. Progression of insulin resistance can lead to metabolic syndrome, nonalcoholic fatty liver disease (NAFLD), and type 2 diabetes mellitus.

The three primary sites of insulin resistance are the muscle, liver, and adipose tissue. Insulin resistance is postulated to begin in muscle tissue with immune-mediated inflammatory change and excess free fatty acids, causing ectopic lipid deposition. Muscle accounts for up to 70% of glucose disposal. With impaired muscle uptake, excess glucose returns to the liver increasing de novo lipogenesis (DNL) and circulating free fatty acids, further contributing to ectopic fat deposition and insulin resistance.

Insulin Resistance - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Insulin Resistance pipeline landscape is provided which includes the disease overview and Insulin Resistance treatment guidelines. The assessment part of the report embraces, in depth Insulin Resistance commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Insulin Resistance collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence R&D Insulin Resistance. The therapies under development are focused on novel approaches to treat/improve Insulin Resistance.

Insulin Resistance Emerging Drugs

AZP-3404: Amolyt Pharma AZP-3404 is the first therapeutic peptide to leverage the biology of insulin-like growth factor binding protein 2 (IGFBP2), a key mediator of the beneficial effects of leptin on fat and glucose metabolism. The metabolic-regulating activity of IGFBP2 resides in a small peptide sequence located within its structure. AZP-3404 is a stabilized peptide analog of this sequence and is the first drug candidate to utilize and to reproduce the unique biology ofIGFBP2.

TNX-1900: Tonix Pharmaceuticals TNX-1900 is based on a proprietary potentiated formulation of oxytocin and is currently being developed as a candidate for prophylaxis of chronic migraine, the treatment of insulin resistance1 and related conditions.TNX-1900 is based on Tonix’s patented intranasal potentiated oxytocin formulation. Tonix is also developing a different intranasal formulation, designated TNX-2900, for the treatment of Prader-Willi syndrome.

Insulin Resistance: Therapeutic Assessment

This segment of the report provides insights about the Insulin Resistance drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Insulin Resistance

There are approx. 8+ key companies which are developing the therapies Insulin Resistance. The companies which have their Insulin Resistance drug candidates in the most advanced stage, i.e Phase III include, Boehringer Ingelheim/Eli Lilly and Company

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Insulin Resistance pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Insulin Resistance: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Insulin Resistance therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Insulin Resistance drugs.

Insulin Resistance Report Insights

• Insulin Resistance Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Insulin Resistance Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Insulin Resistance drugs?
• How many Insulin Resistance drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Insulin Resistance?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Insulin Resistance therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Insulin Resistance and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Boehringer Ingelheim/Eli Lilly and Company
• Tonix Pharmaceuticals
• Corbus Pharmaceuticals
• Amolyt Pharma
• Dompe Farmaceutici

Key Products

• Empagliflozin
• TNX-1900
• CRB 4001
• AZP 3404
• Ladarixin